{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:40:54Z","timestamp":1791945654196,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00520-012-1461-4","type":"journal-article","created":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T18:00:33Z","timestamp":1335463233000},"page":"1353-1360","source":"Crossref","is-referenced-by-count":21,"title":["Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients"],"prefix":"10.1007","volume":"20","author":[{"given":"George","family":"Dranitsaris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Hatzimichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,27]]},"reference":[{"key":"1461_CR1","unstructured":"Carter JA, Snedecor SJ, Kaura S et al (2011) Cost-effectiveness of zoledronic acid versus denosumab in prevention of skeletal-related events in metastatic breast cancer. J Clin Oncol 29, suppl; abstr 9025"},{"key":"1461_CR2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14728210802584217","volume":"13","author":"JC Clark","year":"2008","unstructured":"Clark JC, Dass CR, Choong PF (2008) Current and future treatments of bone metastases. Expert Opin Emerg Drugs 13:609\u201327","journal-title":"Expert Opin Emerg Drugs"},{"issue":"Suppl 4","key":"1461_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14\u201327","journal-title":"Oncologist"},{"key":"1461_CR4","first-page":"341","volume":"4","author":"T Delea","year":"2006","unstructured":"Delea T, McKiernan J, Brandman J et al (2006) Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 4:341\u20137","journal-title":"J Support Oncol"},{"key":"1461_CR5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/11584210-000000000-00000","volume":"29","author":"G Dranitsaris","year":"2011","unstructured":"Dranitsaris G, Truter I, Lubbe MS et al (2011) Advances in cancer therapeutics and patient access to new drugs. PharmacoEconomics 29:213\u201324","journal-title":"PharmacoEconomics"},{"key":"1461_CR6","unstructured":"FDA Approval for Denosumab. November 18, 2010. Available at http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-denosumab . Accessed 15 August 2011"},{"key":"1461_CR7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u201322","journal-title":"Lancet"},{"key":"1461_CR8","unstructured":"Good PI, Hardin JW (2006) Common errors in statistics. Wiley, New Jersey, pp 80\u201384"},{"key":"1461_CR9","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1001\/jama.1993.03510210084032","volume":"270","author":"GH Guyatt","year":"1993","unstructured":"Guyatt GH, Sackett DL, Cook DJ (1993) User\u2019s guides to the medical literature; how to use an article about therapy or prevention A. JAMA 270:2598\u20132601","journal-title":"JAMA"},{"key":"1461_CR10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1994.03510250075039","volume":"271","author":"GH Guyatt","year":"1994","unstructured":"Guyatt GH, Sackett DL, Cook DJ (1994) User\u2019s guides to the medical literature; how to use an article about therapy or prevention B. JAMA 271:59\u201363","journal-title":"JAMA"},{"key":"1461_CR11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u201332","journal-title":"J Clin Oncol"},{"key":"1461_CR12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.7326\/0003-4819-126-9-199705010-00007","volume":"126","author":"J Henry","year":"1997","unstructured":"Henry J, McQuary DM, Moore AR (1997) Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126:712\u201320","journal-title":"Ann Intern Med"},{"key":"1461_CR13","first-page":"317","volume":"14","author":"MJ Lage","year":"2008","unstructured":"Lage MJ, Barber BL, Harrison DJ, Jun S (2008) The cost of treating skeletal-related events in patients with prostate cancer. Am J Manage Care 14:317\u201322","journal-title":"Am J Manage Care"},{"key":"1461_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/SPC.0b013e32830baac2","volume":"2","author":"A Lipton","year":"2008","unstructured":"Lipton A, Jun S (2008) RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2:197\u2013203","journal-title":"Curr Opin Support Palliat Care"},{"key":"1461_CR15","unstructured":"Martin M, Steger G, von Moos R, et al (2011) Benefit of denosumab therapy in patients with bone metastases from breast cancer: a number-needed-to-treat (NNT) analysis on behalf of the 136 study investigators [abstract]. Presented at the 12th St. Gallen International Breast Cancer Conference; 16\u201319 March; St. Gallen, Switzerland. Abstract P347"},{"key":"1461_CR16","doi-asserted-by":"crossref","unstructured":"Miller K, Fizazi K, Smith M, et al. (2011) Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: a number-needed-to-treat (NNT) analysis [abstract]. Presented at the AUA Annual Meeting; 14\u201319 May; Washington, DC. Abstract 648","DOI":"10.1016\/j.juro.2011.02.1550"},{"key":"1461_CR17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M N\u00f8rgaard","year":"2010","unstructured":"N\u00f8rgaard M, Jensen A\u00d8, Jacobsen JB et al (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162\u20137","journal-title":"J Urol"},{"key":"1461_CR18","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474. doi: 10.1002\/14651858.CD003474.pub2","DOI":"10.1002\/14651858.CD003474.pub2"},{"key":"1461_CR19","doi-asserted-by":"crossref","unstructured":"Richardson GE, Ciuleanu TE, Costa L et al (2011) Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: a number needed to treat (NNT) analysis. J Clin Oncol 29, suppl; abstr 9115","DOI":"10.1200\/jco.2011.29.15_suppl.9115"},{"key":"1461_CR20","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/bmj.317.7165.1075","volume":"317","author":"M Roland","year":"1998","unstructured":"Roland M, Torgerson D (1998) Understanding controlled trials: what outcomes should be measured? BMJ 317:1075","journal-title":"BMJ"},{"key":"1461_CR21","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664","journal-title":"N Engl J Med"},{"key":"1461_CR22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36\u201343","journal-title":"Cancer"},{"key":"1461_CR23","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"1461_CR24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2174\/156800909789760375","volume":"9","author":"D Santini","year":"2009","unstructured":"Santini D, Fratto ME, Vincenzi B et al (2009) Denosumab: the era of targeted therapies in bone metastatic diseases. Curr Cancer Drug Targets 9:834\u2013842","journal-title":"Curr Cancer Drug Targets"},{"key":"1461_CR25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/J.1524-4733.2002.55150.x","volume":"5","author":"E Schechtman","year":"2002","unstructured":"Schechtman E (2002) Odds ratio, relative risk, absolute risk reduction, and the number needed to treat\u2014which of these should we use? Value Health 5:431\u20136","journal-title":"Value Health"},{"key":"1461_CR26","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20139","journal-title":"J Clin Oncol"},{"key":"1461_CR27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.2010.33.5596","volume":"29","author":"H West","year":"2011","unstructured":"West H (2011) Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol 29:1095\u20138","journal-title":"J Clin Oncol"},{"key":"1461_CR28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.18553\/jmcp.2011.17.8.621","volume":"17","author":"J Xie","year":"2011","unstructured":"Xie J, Namjoshi M, Wu EQ et al (2011) Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 17:621\u201343","journal-title":"J Manag Care Pharm"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00520-012-1461-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T08:12:41Z","timestamp":1642147961000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1461-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,27]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1461"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1461-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,27]]}}}